Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Peringkat dalam Saham #174
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity,... Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Harga Saham
$62.26
Terakhir disinkronkan: 2026-09-22
Kapitalisasi Pasar
$127.18B
Perubahan (1 hari)
-0.78%
Perubahan (1 tahun)
38.63%
Negara
US
Perdagangan Bristol-Myers Squibb Company (BMY)

Kategori

Rasio P/B untuk Bristol-Myers Squibb Company (BMY)
Rasio P/B per September 2026 TTM: 5.86
Menurut laporan keuangan dan harga saham terbaru dari Bristol-Myers Squibb Company, rasio P/B saat ini (TTM) adalah 5.86. Pada akhir 2024, rasio P/B perusahaan adalah 7.02.
Riwayat rasio P/B untuk Bristol-Myers Squibb Company dari 2000 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
2026 (TTM) 5.86 -100.00%
2025 0.00 -100.00%
2024 7.02 94.57%
2023 3.61 -26.89%
2022 4.93 28.08%
2021 3.85 4.03%
2020 3.70 74.59%
2019 2.12 -64.94%
2018 6.05 -29.54%
2017 8.59 42.23%
2016 6.04 -24.90%
2015 8.04 22.05%
2014 6.59 14.22%
2013 5.77 44.33%
2012 4.00 6.41%
2011 3.75 30.06%
2010 2.89 -14.03%
2009 3.36 -10.57%
2008 3.76 -24.09%
2007 4.95 -4.20%
2006 5.16 29.01%
2005 4.00 -17.94%
2004 4.88 -13.85%
2003 5.66 7.21%
2002 5.28 -51.57%
2001 10.90 -27.65%
2000 15.07 0.00%
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
29.9692 411.02%
US
7.6479 30.41%
US
-78.0908 -1,431.56%
US
8.4776 44.56%
CH
8.5385 45.59%
US